|
Schirdewan博士的引述的參考文獻:
. T a! ?) p! n: D2 H$ c( G Y9 |( z0 n4 K6 T( [# k
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
; ^2 U1 J* U9 n% ~+ k5 o
8 i8 a0 U0 w* O" {7 `7 hDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
& J* M8 M% |, T4 R$ m. r; [" h3 Z' Y+ C6 V6 S' R
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
) Y* G( {2 l5 C$ y( |, f4 P0 _# S8 b, N6 W
關於BIOTRONIK SE & Co. KG6 u/ g, w# B+ Y, R5 {9 O7 u6 U
/ E, j1 x5 N- L9 i. G% k# j& S; aBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|